The European trauma device market will see modest growth through 2027. Financial constraints and the increasing presence of GPOs will, however, contribute to downward ASP pressures, limiting revenue growth to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for trauma devices in Europe across a 10-year period.
Several manufacturers have recently expanded their product portfolios with the introduction of new devices or by acquiring companies with complementary products.
Which competitors are using the breadth of their product portfolios to secure trauma device market shares?
Which companies have expanded their offerings?
Which segments are seeing increased interest from competitors, and why?
The European trauma device market will continue to grow through 2027.
Which product segments will see the greatest increases in unit volumes through 2027, and why?
Which device segments are seeing revenue declines, and what is contributing to this?
How are procedural trends shifting due to improved technology and clinical data?
Rising awareness among patients and increased surgical training will drive demand for patient-specific implants; however, uptake of premium-priced products will be somewhat restricted by hospital budget constraints.
Which type of premium and patient-specific devices will continue to display revenue growth despite these pressures?
Which countries will face the greatest pricing pressure?
How will the adoption of premium-priced products affect sales in competing product segments?
The introduction of the new MDR will lead to consolidation in some segments of the European trauma device market.
Which segments and manufacturers will be most affected by the new MDR?
How will competitors leverage the MDR to their advantage?
- Trauma Devices - Market Insights - Europe
Author(s): Robert Cohen, BSc
Robert is an analyst within the Orthopedics, Dental, and Aesthetics Medtech Insights team at Decision Resources Group, specializing in aesthetic injectables, therapeutic botulinum toxin, cosmetic threads, breast reconstruction, and bone graft substitutes. Prior to joining DRG, Robert worked as a clinical research assistant in hematology. Robert holds an Honors Bachelor's degree in Immunology from McGill University.